Use of photobiomodulation in users of the breastfeeding clinic in the SUS-BH network

Breastfeeding clinic in the SUS-BH network: characterization of users of the service and use of Photobiomodulation in nipple trauma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-7mhpvxk

Enrollment

Unknown

Registered

2023-06-15

Start date

2021-08-09

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Measurement

Interventions

This is a randomized, double-blind clinical trial. Participants will be divided into two groups. 25 participants will be allocated in each of the groups. The intervention group will receive a red lase

continuous emission mode, punctual (at the site of injury), without contact

frequency of 100 Hz

power of 100mw

energy of 1 J, lasting 10 seconds. For analgesia, a DMC laser device will be used, with the following dosimetric parameters: light wavelength of 810 nm

continuous, punctual, contact emission mode

energy of 4 J, in a cross shape, on the areola, lasting 40 seconds at each point. The study is characterized as double-blind because the participants will not know if they were allocated in the interv

E02.594

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Postpartum women over 18 years old; nursing mothers; with a diagnosis of abrasions, breast fissures or ulcerations in at least one of the breasts; absence of cognitive deficit; absence of malignant alterations for puerperal women; absence of ankyloglossia with indication of frenotomy for babies

Exclusion criteria

Exclusion criteria: Postpartum women who have photosensitivity or any adverse reactions to exposure to sunlight; who is pregnant; who is using other forms of treatment for nipple trauma (ointments, sunbathing, own milk, among others); undiagnosed lesions on the area to be irradiated or close to it; infection at the application site; use of a pacemaker or other electronic implant; who present a diagnosis of mastitis or breast candidiasis, during the development of the study, according to a medical evaluation

Design outcomes

Primary

Measure	Time frame
It is expected to verify a reduction in the area of ??the lesion, by measuring the area of ??the lesion before and after the intervention	—

Secondary

Measure	Time frame
It is expected to verify pain reduction, through the use of the visual analogue pain scale, pre and post intervention	—

Countries

Brazil

Contacts

Public ContactCamila Martins

Universidade Federal de Minas Gerais

camiladantas@pbh.gov.br+5531988547090

Outcome results

None listed

Source: REBEC (via WHO ICTRP)